-
Ab183441-5mgFaralimomab (anti-IFNAR-1) is an immunomodulator, and a murine anti-IFNA1 IgG1 mAb.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab183441-1mgFaralimomab (anti-IFNAR-1) is an immunomodulator, and a murine anti-IFNA1 IgG1 mAb.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab183441-10mgFaralimomab (anti-IFNAR-1) is an immunomodulator, and a murine anti-IFNA1 IgG1 mAb.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab183441-100μgFaralimomab (anti-IFNAR-1) is an immunomodulator, and a murine anti-IFNA1 IgG1 mAb.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level<: 1.0EU/mg.
-
Ab183438-5mgMatuzumab (anti-EGFR) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level <: 0.01EU/μg.
-
Ab183438-1mgMatuzumab (anti-EGFR) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level <: 0.01EU/μg.
-
Ab183438-10mgMatuzumab (anti-EGFR) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level <: 0.01EU/μg.
-
Ab183438-100μgMatuzumab (anti-EGFR) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth.Purity>:95% (SDS-PAGE&:SEC)Endotoxin Level <: 0.01EU/μg.
-
Ab183427-5mgPonezumab (anti-Amyloid Beta) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab (anti-Amyloid Beta) reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab
-
Ab183427-1mgPonezumab (anti-Amyloid Beta) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab (anti-Amyloid Beta) reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab
-
Ab183427-10mgPonezumab (anti-Amyloid Beta) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab (anti-Amyloid Beta) reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab
-
Ab183427-100μgPonezumab (anti-Amyloid Beta) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab (anti-Amyloid Beta) reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab